Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 1998

View Archived Issues

Spotlight on angiogenesis inhibitors in clinical testing

Gene transfer may be an effective strategy for treatment of AIDS-related Kaposi's sarcoma

Caroverine shown to effective treatment for alcohol withdrawal syndrome

Bactericidal actions of plaunotol demonstrated

Novel antiulcer agent effectively reduces gastric bleeding and lesion formation in rats

Elan to acquire Kodak's NanoSystems division

Sugen initiates two new trials with lead compound

Cell Genesys announces positive phase I/II results using GVAX vaccine for prostate cancer

AxyS Pharmaceuticals reaches milestone in Bristol-Myers Squibb collaboration

Procyon receives U.S. patent for the use of ANAs in the treatment of cancer

Novartis to consolidate cell and gene therapy operations

Nortran completes phase II trial of RSD-921

Genetronics reports continued success with electroporation therapy of cancer

Toa Eiyo discloses new adenosine A1 antagonists

New NOS inhibitors prepared at Ono described in patent literature

TAN-2474 compounds from Gliocladium act as complement inhibitors

Takeda describes preparation and use of inhibitors of steroid C17-20 lyase

Collaborative work by Otsuka and Taiho leads to broad-spectrum, water-soluble cephems

Kyowa Hakko reports success in its search for new analgesics

Sodium channel blocker with antiischemic potential emerges from Glaxo Wellcome R&D

Another mGluR1 receptor ligand reported by Lilly

New from Banyu: M3-selective muscarinic antagonists with excellent activity, improved safety

New target for treating HCV infection: NS3-4A proteinase

Neutralase preclinical data published; clinical trial still on hold

Cephalon presents CEP-701 at German cancer meeting

PAF antagonist evaluated in patients with rheumatoid arthritis; results disappointing

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...